<html><body><pre>[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4982 Introduced in House (IH)]

&lt;DOC&gt;






114th CONGRESS
  2d Session
                                H. R. 4982

To direct the Comptroller General of the United States to evaluate and 
      report on the in-patient and outpatient treatment capacity, 
             availability, and needs of the United States.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 18, 2016

Mr. Foster (for himself and Mr. Pallone) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To direct the Comptroller General of the United States to evaluate and 
      report on the in-patient and outpatient treatment capacity, 
             availability, and needs of the United States.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Examining Opioid Treatment 
Infrastructure Act of 2016''.

SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE.

    Not later than 24 months after the date of enactment of this Act, 
the Comptroller General of the United States shall initiate an 
evaluation, and submit to Congress a report, of the in-patient and 
outpatient treatment capacity, availability, and needs of the United 
States, which shall include, to the extent data is available--
            (1) the capacity of acute residential or inpatient 
        detoxification programs;
            (2) the capacity of inpatient clinical stabilization 
        programs, transitional residential support services, and 
        residential rehabilitation programs;
            (3) the capacity of demographic specific residential or 
        inpatient treatment programs, such as those designed for 
        pregnant women or adolescents;
            (4) geographical differences of the availability of 
        residential and outpatient treatment and recovery options for 
        substance use disorders across the continuum of care;
            (5) the availability of residential and outpatient 
        treatment programs that offer treatment options based on 
        reliable scientific evidence of efficacy for the treatment of 
        substance use disorders, including the use of Food and Drug 
        Administration-approved medicines and evidence-based 
        nonpharmacological therapies;
            (6) the number of patients in residential and specialty 
        outpatient treatment services for substance use disorders; and
            (7) an assessment of the need for residential and 
        outpatient treatment for substance use disorders across the 
        continuum of care.
                                 &lt;all&gt;
</pre></body></html>
